Atypical course of COVID-19 in patient with Bruton agammaglobulinemia
Ivana Milošević, Jaroslava Jovanović, Olja Stevanović
Abstract
We present atypical course of the novel coronavirus disease (COVID-19) in 34-year man with Bruton agammaglobulinemia. The patient was successfully treated by a combination of available drugs, including convalescent plasma and interleukin-6 (IL-6) inhibitor.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicineX-linked agammaglobulinemiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Compassionate Use2019-20 coronavirus outbreakCoronavirusImmunologyVirologyDiseaseBruton's tyrosine kinaseInfectious disease (medical specialty)Internal medicineTyrosine kinaseOutbreakClinical trialReceptorImmunodeficiency and Autoimmune DisordersChronic Lymphocytic Leukemia ResearchBlood disorders and treatments